Bombesin regulates cyclin D1 expression through the early growth response protein Egr-1 in prostate cancer cells

被引:46
作者
Xiao, DM
Chinnappan, D
Pestell, R
Albanese, C
Weber, HC
机构
[1] Boston Univ, Sch Med, Gastroenterol Sect, EBRC, Boston, MA 02118 USA
[2] Georgetown Univ, Ctr Canc, Lombardi Comprehens Canc Ctr, Dept Oncol, Washington, DC USA
关键词
D O I
10.1158/0008-5472.CAN-05-1830
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Our previous studies indicate that the activation of mitogen-activated protein kinase (MAPK) pathway is involved in bombesin-induced cell proliferation in prostate cancer cells. Cyclin D1 is a critical regulator involved in cell cycle progression through the G(1) phase into the S phase, thereby contributing to cell proliferation. Mostly, mitogen-stimulated expression of cyclin D1 is attributed to the extracellular signal-regulated kinase (ERK) activation. Here, we found that bombesin induced human cyclin D1 expression on both mRNA and protein levels in DU-145 prostate cancer cells. Mutational analyses showed that bombesin-enhanced cyclin D1 transcription required the binding of nuclear proteins to the -143 to -105 region of the human cyclin D1 promoter, which contains binding sites for transcription factors Sp-1 and early growth response protein (Egr-1). Do novo protein synthesis was requisite for bombesin-induced cyclin D1 expression. Further studies showed Egr-1 was induced upon bombesin stimulation. The induction of Egr-1 expression and its binding to the cyclin D1 promoter were essential for bombesin-enhanced cyclin D1 transcription. Inhibition of MAPK pathway with either the MEK1 inhibitor PD98059 or a dominant-negative Ras mutant, RasN17, abolished bombesin-induced cyclin D1 activation. Taken. together, bombesin-induced cyclin D1 expression in prostate cancer cells is mediated by Egr-1 activation and the interaction of Egr-1 with the Egr-1/Sp1 motif of the cyclin D1 promoter through the activation of MAPK pathway. These findings represent a novel mechanism of bombesin-dependent stimulation of mitogenesis by regulating directly the cell cycle in prostate cancer.
引用
收藏
页码:9934 / 9942
页数:9
相关论文
共 54 条
[1]   Impaired prostate tumorigenesis in Egr1-deficient mice [J].
Abdulkadir, SA ;
Qu, ZC ;
Garabedian, E ;
Song, SK ;
Peters, TJ ;
Svaren, J ;
Carbone, JM ;
Naughton, CK ;
Catalona, WJ ;
Ackerman, JJH ;
Gordon, JI ;
Humphrey, PA ;
Milbrandt, J .
NATURE MEDICINE, 2001, 7 (01) :101-107
[2]   TRANSFORMING P21(RAS) MUTANTS AND C-ETS-2 ACTIVATE THE CYCLIN D1 PROMOTER THROUGH DISTINGUISHABLE REGIONS [J].
ALBANESE, C ;
JOHNSON, J ;
WATANABE, G ;
EKLUND, N ;
VU, D ;
ARNOLD, A ;
PESTELL, RG .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (40) :23589-23597
[3]   Activating transcription factor 3 induces DNA synthesis and expression of cyclin D1 in hepatocytes [J].
Allan, AL ;
Albanese, C ;
Pestell, RG ;
LaMarre, J .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (29) :27272-27280
[4]   Neuroendocrine cells in prostate cancer [J].
Amorino, GP ;
Parsons, SJ .
CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION, 2004, 14 (04) :287-300
[5]  
Aprikian AG, 1998, PROSTATE, P52
[6]   Bombesin specifically induces intracellular calcium mobilization via gastrin-releasing peptide receptors in human prostate cancer cells [J].
Aprikian, AG ;
Han, K ;
Chevalier, S ;
Bazinet, M ;
Viallet, J .
JOURNAL OF MOLECULAR ENDOCRINOLOGY, 1996, 16 (03) :297-306
[7]   Reciprocal regulation of β1-adrenergic receptor gene transcription by Sp1 and early growth response gene 1:: Induction of EGR-1 inhibits the expression of the β1-adrenergic receptor gene [J].
Bahouth, SW ;
Beauchamp, MJ ;
Vu, KN .
MOLECULAR PHARMACOLOGY, 2002, 61 (02) :379-390
[8]   Antisense to the early growth response-1 gene (Egr-1) inhibits prostate tumor development in TRAMP mice [J].
Baron, V ;
Duss, S ;
Rhim, JH ;
Mercola, D .
THERAPEUTIC OLIGONUCLEOTIDES: ANTISENSE, RNAI, TRIPLE-HELIX, GENE REPAIR, ENHANCER DECOYS, CPG AND DNA CHIPS, 2003, 1002 :197-216
[9]   Inhibition of Egr-1 expression reverses transformation of prostate cancer cells in vitro and in vivo [J].
Baron, V ;
De Gregorio, G ;
Krones-Herzig, A ;
Virolle, T ;
Calogero, A ;
Urcis, R ;
Mercola, D .
ONCOGENE, 2003, 22 (27) :4194-4204
[10]  
Bartholdi MF, 1998, INT J CANCER, V79, P82, DOI 10.1002/(SICI)1097-0215(19980220)79:1<82::AID-IJC16>3.0.CO